LncRNA LOXL1-AS1 promotes ovarian cancer progression by enhanced BRIP1 mRNA stability.

IF 3.5 4区医学 Q2 ONCOLOGY

Medical Oncology Pub Date : 2025-09-30 DOI:10.1007/s12032-025-03055-y

Su Wan, Chang Su, Jin Ding, Ji Liu, Lingli He, Lifen Liu, Qi Peng, Guantai Ni, Weipei Zhu

{"title":"LncRNA LOXL1-AS1 promotes ovarian cancer progression by enhanced BRIP1 mRNA stability.","authors":"Su Wan, Chang Su, Jin Ding, Ji Liu, Lingli He, Lifen Liu, Qi Peng, Guantai Ni, Weipei Zhu","doi":"10.1007/s12032-025-03055-y","DOIUrl":null,"url":null,"abstract":"<p><p>Long non-coding RNAs (lncRNAs) have crucial effects on the development of malignant tumors. This work focused on determining how LOXL1-AS1 contributed to epithelial ovarian cancer development. As indicated by quantitative RT-polymerase chain reaction (qRT-PCR), LOXL1-AS1 showed significant overexpression within ovarian epithelial cancer tissues and ovarian cancer cells compared with non-cancer samples and regular human epithelial cell lines. According to CCK-8, flow cytometry, plate cloning, cell scratch test, a series of cell function tests in vitro, a nude mouse transplanted tumor model, and Western blot assays, LOXL1-AS1 siRNA transfection suppressed the growth, invasion, and epithelial-to-mesenchymal transformation characteristics of SKOV3 and A2780 cells in vitro and vivo. As discovered, LOXL1-AS1 targets BRCA1-interacting protein C-terminal helicase 1 (BRIP1) mRNA, resulting in a malignant phenotype of ovarian cancer. Overexpression of BRIP1 reversed the inhibition of cell progression induced by LOXL1-AS1 siRNA. In addition, based on RNA stability experiments, LOXL1-AS1 enhanced ovarian cancer cell growth and metastasis by stabilizing BRIP1 mRNA. Our findings reveal a novel mechanism of how LOXL1-AS1 enhances epithelial ovarian cancer progression by specifically regulating BRIP1 mRNA stability. This provides the potential therapeutic application of LOXL1-AS1 targeting BRIP1 for treating ovarian cancer.</p>","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 11","pages":"504"},"PeriodicalIF":3.5000,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12032-025-03055-y","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Long non-coding RNAs (lncRNAs) have crucial effects on the development of malignant tumors. This work focused on determining how LOXL1-AS1 contributed to epithelial ovarian cancer development. As indicated by quantitative RT-polymerase chain reaction (qRT-PCR), LOXL1-AS1 showed significant overexpression within ovarian epithelial cancer tissues and ovarian cancer cells compared with non-cancer samples and regular human epithelial cell lines. According to CCK-8, flow cytometry, plate cloning, cell scratch test, a series of cell function tests in vitro, a nude mouse transplanted tumor model, and Western blot assays, LOXL1-AS1 siRNA transfection suppressed the growth, invasion, and epithelial-to-mesenchymal transformation characteristics of SKOV3 and A2780 cells in vitro and vivo. As discovered, LOXL1-AS1 targets BRCA1-interacting protein C-terminal helicase 1 (BRIP1) mRNA, resulting in a malignant phenotype of ovarian cancer. Overexpression of BRIP1 reversed the inhibition of cell progression induced by LOXL1-AS1 siRNA. In addition, based on RNA stability experiments, LOXL1-AS1 enhanced ovarian cancer cell growth and metastasis by stabilizing BRIP1 mRNA. Our findings reveal a novel mechanism of how LOXL1-AS1 enhances epithelial ovarian cancer progression by specifically regulating BRIP1 mRNA stability. This provides the potential therapeutic application of LOXL1-AS1 targeting BRIP1 for treating ovarian cancer.

查看原文本刊更多论文

LncRNA LOXL1-AS1通过增强BRIP1 mRNA稳定性促进卵巢癌进展。

长链非编码rna （Long non-coding rna, lncRNAs）在恶性肿瘤的发生发展中起着至关重要的作用。这项工作的重点是确定LOXL1-AS1如何促进上皮性卵巢癌的发展。定量rt -聚合酶链反应（qRT-PCR）结果显示，与非癌样和正常人上皮细胞系相比，LOXL1-AS1在卵巢上皮癌组织和卵巢癌细胞中过表达。CCK-8、流式细胞术、平板克隆、细胞划痕实验、一系列体外细胞功能实验、裸鼠移植瘤模型、Western blot等实验结果表明，转染LOXL1-AS1 siRNA可抑制SKOV3和A2780细胞在体外和体内的生长、侵袭和上皮-间质转化特性。发现LOXL1-AS1靶向brca1相互作用蛋白c -末端解旋酶1 (BRIP1) mRNA，导致卵巢癌的恶性表型。BRIP1的过表达逆转了LOXL1-AS1 siRNA诱导的细胞进展抑制。此外，基于RNA稳定性实验，LOXL1-AS1通过稳定BRIP1 mRNA促进卵巢癌细胞生长和转移。我们的研究结果揭示了LOXL1-AS1如何通过特异性调节BRIP1 mRNA的稳定性来促进上皮性卵巢癌进展的新机制。这为靶向BRIP1的LOXL1-AS1治疗卵巢癌提供了潜在的治疗应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Medical Oncology 医学-肿瘤学

CiteScore

4.20

自引率

2.90%

发文量

259

审稿时长

1.4 months

期刊介绍： Medical Oncology (MO) communicates the results of clinical and experimental research in oncology and hematology, particularly experimental therapeutics within the fields of immunotherapy and chemotherapy. It also provides state-of-the-art reviews on clinical and experimental therapies. Topics covered include immunobiology, pathogenesis, and treatment of malignant tumors.